Preclinical Murine Models for Lung Cancer: Clinical Trial Applications

被引:114
作者
Kellar, Amelia [1 ]
Egan, Cay [1 ]
Morris, Don [1 ]
机构
[1] Univ Calgary, Dept Med Oncol, Calgary, AB T2N 4N2, Canada
关键词
SMALL-CELL LUNG; EPIDERMAL-GROWTH-FACTOR; PHASE-II TRIAL; POSITRON-EMISSION-TOMOGRAPHY; TYROSINE KINASE INHIBITOR; IN-VIVO; ANTITUMOR-ACTIVITY; MOUSE MODELS; TUMOR-GROWTH; T-ANTIGEN;
D O I
10.1155/2015/621324
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Murine models for the study of lung cancer have historically been the backbone of preliminary preclinical data to support early human clinical trials. However, the availability of multiple experimental systems leads to debate concerning which model, if any, is best suited for a particular therapeutic strategy. It is imperative that these models accurately predict clinical benefit of therapy. This review provides an overview of the current murine models used to study lung cancer and the advantages and limitations of each model, as well as a retrospective evaluation of the uses of each model with respect to accuracy in predicting clinical benefit of therapy. A better understanding of murine models and their uses, as well as their limitations may aid future research concerning the development and implementation of new targeted therapies and chemotherapeutic agents for lung cancer.
引用
收藏
页数:17
相关论文
共 122 条
[31]   Molecular origins of cancer: Lung cancer [J].
Herbst, Roy S. ;
Heymach, John V. ;
Lippman, Scott M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (13) :1367-1380
[32]   Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma models [J].
Herbst, RS ;
Takeuchi, H ;
Teicher, BA .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1998, 41 (06) :497-504
[33]  
Horio Y, 1996, MOL CARCINOGEN, V17, P217, DOI 10.1002/(SICI)1098-2744(199612)17:4<217::AID-MC5>3.0.CO
[34]  
2-A
[35]   Effects of Vandetanib on Lung Adenocarcinoma Cells Harboring Epidermal Growth Factor Receptor T790M Mutation In vivo [J].
Ichihara, Eiki ;
Ohashi, Kadoaki ;
Takigawa, Nagio ;
Osawa, Masahiro ;
Ogino, Atsuko ;
Tanimoto, Mitsune ;
Kiura, Katsuyuki .
CANCER RESEARCH, 2009, 69 (12) :5091-5098
[36]   mda-7 in combination with bevacizumab treatment produces a synergistic and complete inhibitory effect on lung tumor xenograft [J].
Inoue, Satoshi ;
Hartman, Amanda ;
Branch, Cynthia D. ;
Bucana, Corazan D. ;
Bekele, Benjamin N. ;
Stephens, L. Clifton ;
Chada, Sunil ;
Ramesh, Rajagopal .
MOLECULAR THERAPY, 2007, 15 (02) :287-294
[37]   Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras [J].
Jackson, EL ;
Willis, N ;
Mercer, K ;
Bronson, RT ;
Crowley, D ;
Montoya, R ;
Jacks, T ;
Tuveson, DA .
GENES & DEVELOPMENT, 2001, 15 (24) :3243-3248
[38]   ANTITUMOR-ACTIVITY OF THE 2 EPIPODOPHYLLOTOXIN DERIVATIVES VP-16 AND VM-26 IN PRECLINICAL SYSTEMS - A COMPARISON OF INVITRO AND INVIVO DRUG-EVALUATION [J].
JENSEN, PB ;
ROED, H ;
SKOVSGAARD, T ;
FRICHE, E ;
VINDELOV, L ;
HANSEN, HH ;
SPANGTHOMSEN, M .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1990, 27 (03) :194-198
[39]   LKB1 modulates lung cancer differentiation and metastasis [J].
Ji, Hongbin ;
Ramsey, Matthew R. ;
Hayes, D. Neil ;
Fan, Cheng ;
McNamara, Kate ;
Kozlowski, Piotr ;
Torrice, Chad ;
Wu, Michael C. ;
Shimamura, Takeshi ;
Perera, Samanthi A. ;
Liang, Mei-Chih ;
Cai, Dongpo ;
Naumov, George N. ;
Bao, Lei ;
Contreras, Cristina M. ;
Li, Danan ;
Chen, Liang ;
Krishnamurthy, Janakiraman ;
Koivunen, Jussi ;
Chirieac, Lucian R. ;
Padera, Robert F. ;
Bronson, Roderick T. ;
Lindeman, Neal I. ;
Christiani, David C. ;
Lin, Xihong ;
Shapiro, Geoffrey I. ;
Jaenne, Pasi A. ;
Johnson, Bruce E. ;
Meyerson, Matthew ;
Kwiatkowski, David J. ;
Castrillon, Diego H. ;
Bardeesy, Nabeel ;
Sharpless, Norman E. ;
Wong, Kwok-Kin .
NATURE, 2007, 448 (7155) :807-U7